Infection and atherosclerosis

Česká verzia

Authors: P. Syrovátka ¹; P. Kraml ²
Authors place of work: Klinika kardiologie IKEM Praha, přednosta prof. MUDr. Jan Kautzner, CSc., FESC ¹; II. interní klinika 3. lékařské fakulty UK a FN Královské Vinohrady, Praha, přednosta prof. MUDr. Michal Anděl, CSc. ²
Published in the journal: Vnitř Lék 2007; 53(3): 286-291
Category: Review

Summary

Atherosclerosis is a chronic inflammation and the cause of most cardiovascular diseases. It is the main cause of death in the Western world today, even though growing incidence of atherosclerosis-related diseases has been recently observed in developing countries, too. In many patients with atherosclerosis, however, traditional risk factors for atherosclerosis are not identifiable. This has renewed the interest, in recent years, in the links between atherosclerosis and environmental exposures, including infectious agents. Infection was identified as as risk factor for atherosclerosis in the first half of the 20th century. Experimental and clinical studies have shown that infection can stimulate atherogenic processes and that there are significant interactions between infection and traditional risk factors. Yet there are questions concerning etiology, pathogenesis and appropriate interventions which remain unanswered. The following article provides an overview of the role of the infectious agents in atherosclerosis and discusses possible intervention strategies.

Key words:
atherosclerosis – infection – pathogen burden – molecular mimicry – heat shock proteins – endotoxin – Chlamydia pneumoniae - Cytomegalovirus

Zdroje

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.

2. Ophuls W. Arteriosclerosis and cardiovascular disease, their relation to infectious diseases. JAMA 1921; 76: 700-701.

3. Fabricant CG, Fabricant J, Litrenta MM et al. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-340.

4. Epstein SE, Zhu J, Burnett MS et al. Molecular Mimicry Infection and Atherosclerosis Potential Roles of Pathogen Burden and Molecular Mimicry. Arterioscler Thromb Vasc Biol 2000; 20: 1417-1420.

5. Kuneš P, Krejsek J Ateroskleróza, imunitní odpověď a protein tepelného šoku HSP 65/60. Cor Vasa 2001; 43: 205-212.

6. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 1547-1559.

7. Kleindienst R, Xu Q, Willeit J et al. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 1993; 142: 1927-1937.

8. Kol A, Sukhova GK, Lichtman AH et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor- alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-307.

9. Xu Q, Luef G, Weimann S et al. Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein-reactive antisera. Arterioscler Thromb Vasc Biol 1993; 13: 1763-1769.

10. De Nardin E. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Annals of Periodontology 2001; 6: 30-40.

11. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2227-2236.

12. Wiedermann CJ, Kiechl S, Dunzendorfer S et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease. Prospective results from the Bruneck study. J Am Coll Cardiol 1999; 34: 1975-1981.

13. Lehr HA, Sagban TA, Ihling C et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104: 914-920.

14. Seitz CS, Kleindienst R, Xu Q et al. Coexpression of heat-shock protein 60 and intercellular-adhesion molecule-1 is related to increased adhesion of monocytes and T cells to aortic endothelium of rats in response to endotoxin. Lab Invest 1996; 74: 241-252.

15. Levine DM, Parker TS, Donnelly TM et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-12044.

16. Edfeldt K, Swedenborg J, Hansson GK et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-1161.

17. Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.

18. Amar J, Ruidavets JB, Bal Dit Sollier C et al. Soluble CD14 and aortic stiffnessin a population-based study. J Hypertens. 2003; 21: 1869-1877.

19. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436

20. Zeman K, Pospíšil L, Anderle J et al. Direct and indirect evidence of Chlamydia pneumoniae in patients with significant stenosis of a. carotis of atherosclerotic origin. Scripta Medica 2004; 77: 173-180.

21. Zeman K, Pospíšil L, Medková Z et al. Účast chlamydiové infekce ve vztahu k ukazatelům lipémie v etiologii nestabilní anginy pectoris. Vnitř Lék 2003; 49: 555-558.

22. Anderson JL, Muhlestein JB, Carlquist J et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-1547.

23. O’Connor CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-1466

24. Cercek B, Shah PK, Noc M et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-813.

25. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993; 14: 30-38.

26. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.

27. Altannavch TS, Roubalová K, Kučera P et al. Effect of human cytomegalovirus and glucose on adhesion molecules expression in cultured human endothelial cells. Acta Virol 2002; 46: 183-185.

28. Vliegen I, Duijvestijn A, Grauls G et al. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect 2004; 6: 17-24.

29. Ignatius WF. Infections and their role in atherosclerotic vascular disease. JADA 2002; 133: 7-13.

30. Hujoel PP, Drangsholt M, Spiekeman Ch et al. Periodontal disease and coronary heart disease risk. JAMA 2000; 284: 1406-1410.

31. Li L, Messas E, Batista EL jr et al. Porphyromonas gingivalis Infection Accelerates the Progression of Atherosclerosis in a Heterozygous Apolipoprotein E-Deficient Murine Model. Circulation 2002; 105: 861-867.

32. Beck JD, Elter JR, Heiss G et al. Relationship of Periodontal Disease to Carotid Artery Intima-Media Wall Thickness: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 1816-1822.

33. Epstein SE, Zhu J, Burnett MS et al. Infection and Atherosclerosis: Potential Roles of Pathogen Burden and Molecular Mimicry. Arterioscler Thromb Vasc Biol 2000; 20: 1417-1420.

34. Rupprecht HJ, Blankenberg S, Bickel C et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104: 25-31.

35. Bainton D, Jones GR, Hole D. Influenza and ischeamic heart disease: a possible trigger for acute myocardial infarction? Int J Epidemiol 1978; 7: 231-239.

36. Naghavi M, Banlas Z, Siadaty S. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102: 3039-3045.

37. Etingin OR, Silverstein RL, Friedman HM et al. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 1990; 61: 657-666.

38. Zhou X, Caligiuri G, Hamsten A et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108-114.

39. Maron R, Sukhova G, Faria AM et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1708-1715.

40. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-855.

41. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.

42. Chan G et al. Nonsteroidal antiinflammatory drugs, acetaminophen and the risk of cardiovascular events. Circulation 2006; 113: 1578-1587.

43. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.